Biomea Fusion, Inc. May Have Violated Securities Laws And The Schall Law Firm Urges Affected Shareholders To Join An Inquiry
Biomea Fusion, Inc. (BMEA)
Company Research
Source: Accesswire
Impact Snapshot
Event Time:
BMEA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMEA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMEA alerts
High impacting Biomea Fusion, Inc. news events
Weekly update
A roundup of the hottest topics
BMEA
News
- Biomea Fusion, Inc. (NASDAQ: BMEA) had its price target raised by analysts at Scotiabank from $21.00 to $41.00. They now have a "sector outperform" rating on the stock.MarketBeat
- Biomea Fusion, Inc. (NASDAQ: BMEA) had its price target raised by analysts at HC Wainwright from $15.00 to $40.00. They now have a "buy" rating on the stock.MarketBeat
- FDA Removes Clinical Hold On Biomea Fusion's Early-Stage Trials For Potential Diabetes Candidate [Yahoo! Finance]Yahoo! Finance
- Biomea Fusion, Inc. (NASDAQ: BMEA) had its price target raised by analysts at Barclays PLC from $5.00 to $9.00. They now have an "equal weight" rating on the stock.MarketBeat
- Biomea Fusion, Inc. (NASDAQ: BMEA) was upgraded by analysts at Truist Financial Co. from a "hold" rating to a "buy" rating. They now have a $54.00 price target on the stock.MarketBeat
BMEA
Earnings
- 7/31/24 - In-Line
BMEA
Sec Filings
- 9/27/24 - Form 8-K
- 7/31/24 - Form 10-Q
- 7/31/24 - Form 8-K
- BMEA's page on the SEC website